Publication details
Spektrum cílených léčiv v onkologii optikou molekulární farmakologie
| Title in English | The spectrum of targeted therapy in oncology from the molecular pharmacology perspective |
|---|---|
| Authors | |
| Year of publication | 2019 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The era of targeted drugs in cancer clinical practice began two decades ago when rituximab was authorized for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma, and later trastuzumab was authozied for the treatment of breast cancer. In the middle of August 2019, more than 80 targeted anti-cancer monoclonal antibodies, cytostatics-antibody complexes, protein kinase inhibitors, and other substances that specifically interact with enzymes and other proteins in the cell have been registered in the Czech Republic. Currently, these advanced drugs have their place in the treatment guidelines of various hematological malignancies and solid tumors, especially the adult population. They are used also in pediatric oncology, but more often in the "off-label" regimen, because there is not enough data on their efficacy and safety in the pediatric population. They are also the subject of many clinical trials and academic research projects. There are currently more than 250 clinical trials (CTs) of anticancer drugs with participation of adult patients in the Czech Republic, of which approximately 80% are CTs of targeted drugs, including substances with completely innovative mechanisms of action. The lecture will summarize groups of registered targeted anticancer drugs and mechanisms of their action at the molecular level. Focusing on this dynamically developing part of pharmacotherapy is useful for both clinical oncologists and biomedical researchers, who can help identify the white spots and directions that preclinical and clinical research in this field could pursue. |
| Related projects: |